Top Markets
#1 0G 0G +46.62%
#2 Merlin's Seal BTC Merlin's Seal BTC +42.87%
#3 StonkBroker StonkBroker +34.38%
#4 Useless Coin Useless Coin +29.03%
#5 SAFEcoin SAFEcoin +27.94%
#6 Pons Pons +24.13%
#7 Dogs Dogs +22.45%
#8 rsERG rsERG +21.90%
#9 Zora Zora +20.60%
#10 Verus Coin Verus Coin +19.31%
Coin of the day
0G 0G
Settings
Language
ENGLISH
Currency
USD
Theme
Impact Therap-b Impact Therap-b

Impact Therap-b

7630
Rank in Stocks #13196
IMPACT Therapeutics, a biotechnology firm, specializes in the discovery and... IMPACT Therapeutics, a biotechnology firm, specializes in the discovery and advancement of precision anti-cancer treatments rooted in synthetic lethality, operating across China and international markets. The company's primary offering, Senaparib (IMP4297), is a PARP1/2 inhibitor currently deployed as a first-line maintenance therapy for ovarian cancer. Beyond this, Impact Therapeutics maintains a robust pipeline of investigational drugs. This includes IMP1734, a next-generation PARP1 selective inhibitor undergoing Phase I/II trials as a standalone treatment for advanced solid tumors. Another promising candidate is IMP9064, an ATR kinase selective inhibitor, also in Phase I/II clinical studies for advanced solid tumors as a monotherapy. IMP1707, a PARP1 selective inhibitor capable of penetrating the central nervous system, is in Phase I development for homologous recombination repair-deficient tumors. Additionally, IMP7068, an advanced WEE1 inhibitor, is progressing through Phase I/II clinical trials for various advanced solid tumors. Furthermore, a range of other compounds, namely IMP22, IMP25, IMP08, IMP13, IMP10, IMP27, and IMP32, are in the preclinical development phase. The company, established in 2009, is headquartered in Shanghai, China.
Share Price
$1.85
Market Cap
$510.85M
Change (1 day)
-7.37%
Change (1 year)
-
Country
CN
Trade Impact Therap-b (7630)

Category

Healthcare
Dividend history for Impact Therap-b (7630)
Impact Therap-b (stock symbol: 7630) made a total of 0 dividend payments.
The sum of all dividends (adjusted for stock splits) is : 0.00
Dividend yield (TTM) : 0
Dividend payments for Impact Therap-b (7630) from 2026 to 2026
Annual dividend payments
Year Dividend (stock split adjusted) Change
Not enough data for the provided dates.
List of all dividend payments
Year Dividend Change
Not enough data for the provided dates.
Dividend payments for similar companies or competitors
Company Number of dividend payments Country
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
215.00%
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
225.00%
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
53.00%
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
33.00%
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
223.00%
US